Ustekinumab for Successful Treatment of Refractory Esophageal Crohn's Disease

被引：2

作者：

Barkin, Jodie A. ^{[1
]}

Deshpande, Amar R. ^{[1
]}

机构：

[1] Univ Miami, Leonard M Miller Sch Med, Dept Med, Div Gastroenterol, 1120 NW 14th St,Clin Res Bldg,Suite 1116 D-49, Miami, FL 33136 USA

来源：

ACG CASE REPORTS JOURNAL | 2016年 / 3卷 / 02期

关键词：

D O I：

10.14309/crj.2016.15

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Esophageal involvement in Crohn's disease is rare. We present a case of refractory esophageal Crohn's disease that responded to ustekinumab, which has shown promise in the treatment of refractory, typically intestinal Crohn's disease. There are no prior reports on the successful use of ustekinumab in esophageal Crohn's disease, but should be considered as a possible management strategy in patients with this condition.

引用

下载

页码：107 / +

页数：2

共 50 条

[21] Letter: ustekinumab for the treatment of post-surgical and refractory Crohn's disease
Tursi, Antonio
Mocci, Giammarco
Picchio, Marcello
Elisei, Walter
Maconi, Giovanni
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2021, 53 (07) : 859 - 860
[22] Successful treatment of refractory duodenal Crohn's disease with infliximab
Odashima, Masaru
Otaka, Michiro
Jin, Mario
Horikawa, Youhei
Matsuhashi, Tamostu
Ohba, Reina
Koizumi, Shigeto
Kinoshita, Nobukatsu
Takahashi, Taiji
Watanabe, Sumio
DIGESTIVE DISEASES AND SCIENCES, 2007, 52 (01) : 31 - 32
[23] Successful Treatment of Refractory Duodenal Crohn’s Disease with Infliximab
Masaru Odashima
Michiro Otaka
Mario Jin
Youhei Horikawa
Tamostu Matsuhashi
Reina Ohba
Shigeto Koizumi
Nobukatsu Kinoshita
Taiji Takahashi
Sumio Watanabe
Digestive Diseases and Sciences, 2007, 52 : 31 - 32
[24] Successful treatment of refractory esophageal Crohn's disease with infliximals (vol 46, pg 1733, 2001)
Alsahli, M
DIGESTIVE DISEASES AND SCIENCES, 2002, 47 (05) : 1182 - 1182
[25] Ustekinumab for the treatment of refractory pediatric Crohn's disease: a single-center experience
Cohen, Alexandra
Ahmed, Najma
Sant'Anna, Ana
INTESTINAL RESEARCH, 2021, 19 (02) : 217 - 224
[26] Real-world effectiveness and safety of ustekinumab for the treatment of refractory Crohn's disease: The Scottish ustekinumab cohort
Plevris, N.
Robertson, A.
Fulforth, J.
Hall, R.
Campbell, I.
Kane, C.
Veryan, J.
Lam, W.
Saunders, J.
Jenkinson, P.
Chuah, C.
Kelly, C.
Watts, D.
Gaya, D.
Macdonald, J.
Jafferbhoy, H.
Seenan, J. P.
Mowat, C.
Sutherland, D.
Naismith, G.
Bain, G.
Arnott, I.
Jones, G.
Lees, C.
JOURNAL OF CROHNS & COLITIS, 2020, 14 : S484 - S484
[27] Ustekinumab: Data for the Treatment of Crohn's Disease
Kessing, Richard
ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2023, 61 (08): : 972 - 972
[28] Ustekinumab as Effective Treatment for Refractory Amicrobial Pustulosis of the Folds Associated with Crohn's Disease
Al-Raddadi, Reem
Frances, Camille
Moguelet, Philippe
Bachmeyer, Claude
Guegan, Sarah
ACTA DERMATO-VENEREOLOGICA, 2017, 97 (03) : 389 - 390
[29] Update on Ustekinumab for the Treatment of Crohn's Disease
Leung, Yvette
Panaccione, Remo
GASTROENTEROLOGY CLINICS OF NORTH AMERICA, 2014, 43 (03) : 619 - +
[30] Ustekinumab in super-refractory Crohn's disease patients
Herrera, C.
Robles, V.
Jimenez, C.
Navarro, E.
Casellas, F.
Borruel, N.
JOURNAL OF CROHNS & COLITIS, 2015, 9 : S262 - S263

← 1 2 3 4 5 →